| Description | Christensenella is a Gram-negative, non-spore-forming, anaerobic, and nonmotile genus from the family Christensenellaceae. Christensenella minuta, Christensenella timonensis, and Christensenella massiliensis are currently the only known species of Christensenella, all of which were isolated from Christensenella is a Gram-negative, non-spore-forming, anaerobic, and nonmotile genus from the family Christensenellaceae. Christensenella minuta, Christensenella timonensis, and Christensenella massiliensis are currently the only known species of Christensenella, all of which were isolated from human stool samples. Development of therapeutic applications for Christensenella is an area of active research. Bacteria of the Christensenellaceae family hold great potential for therapeutic use as live biotherapeutic products to treat obesity and associated metabolic disorders. The larger role of Christensenella in the gut microbiome has also been a focal point for understanding how it may relate to other diseases.... Read More | Bifidobacterium are Gram-positive, heterofermentative, anaerobic bacteria with a distinctive bifid; i.e. Y shape after which they are named. They wre originally isolated from the faeces of breast-fed infants, members of the genus Bifidobacterium are commonly found in the GI tract of mammals. In Bifidobacterium are Gram-positive, heterofermentative, anaerobic bacteria with a distinctive bifid; i.e. Y shape after which they are named. They wre originally isolated from the faeces of breast-fed infants, members of the genus Bifidobacterium are commonly found in the GI tract of mammals. In humans, Bifidobacterium resides within the GI tract, from birth to old age. Disturbances in the microbiota are linked to an ever-growing number of immune-linked disease states including IBD, atopic allergy, arthritis, and obesity. Therefore, there is a significant interest in treating these diseases through microbial or "probiotic" supplementation of patients, including Bifidobacterium. Data from mouse models and clinical trials indicate that Bifidobacterium may have beneficial effects for treating and preventing immune-linked diseases, including gut-associated and systemic conditions. Bifidobacterium have been commercially exploited as probiotic agents due to their associated health benefits and GRAS; Generally Recognised As Safe status.... Read More | Human iPSC-Derived Neural Stem Cells that have been genetically edited using CRISPR-Cas9 technology to introduce the G2019S mutation (GGC>AGC) in the LRRK2 gene. This line is homozygous for the G2019S mutation so both alleles contain the mutation.
The G2019S mutation in LRRK2 has been implicated in Human iPSC-Derived Neural Stem Cells that have been genetically edited using CRISPR-Cas9 technology to introduce the G2019S mutation (GGC>AGC) in the LRRK2 gene. This line is homozygous for the G2019S mutation so both alleles contain the mutation.
The G2019S mutation in LRRK2 has been implicated in autosomal-dominant familial Parkinson's disease with late onset (Fonzo et al., 2006, Thaler et al., 2009). The G2019S mutation increases the kinase activity of LRRK2 causing increased autophosphorylation and substrate phosphorylation that may affect neuronal cell health in Parkinson's disease patients (West et al., 2005).... Read More | This product GTTS-WQ4170MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets LAG3 gene. The antibody can be applied in Solid tumors research. | This product is a 93.2 kDa Human SLC13A3 membrane protein expressed in In vitro wheat germ expression system with proprietary liposome technology. The protein is for research use only and is not approved for use in humans or in clinical diagnosis. |